Inbiogen

At a glance

Inbiogen filed 27 disclosures in the last 12 months, including 1 5% holder. The most recent key filing was on Aug 20.

Revenue for 2025 was ₩6.3B, down 10.6% on 2024. It made an operating loss of ₩4.3B. Debt was 1% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.3B and operating loss of ₩1.9B.

The 2025 annual report lists 28 employees with an average tenure of 2.6 years and average pay of ₩48.8M. Its 6 directors and auditors were paid ₩113.5M each on average. It paid no cash dividend for 2025. (주)버킷스튜디오 and related parties held 78.91% at year end.

From the 2025 annual report

Staff: 28 (15 men, 13 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.4B. Directors and auditors: 6, paid ₩680.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)버킷스튜디오 holds 78.89%; with 1 related party the group holds 78.91% of common shares at year end.

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary